StreetAlpha.app
Home › Stocks › OBIO

Orchestra BioMed Holdings, Inc. (OBIO)

Healthcare
$6.97
▼ −2.11%
LAST CLOSE · NOV 17

Orchestra BioMed develops medical device therapies for high blood pressure and artery disease, working with large device makers such as Medtronic. It last closed at $6.97 on Nov 17, down 2.11% on the day. The average 12-month price target from 3 analysts is $11.67 (+67.4% from the last close), with a high of $12.00 and a low of $11.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $144K, the largest $144K.

AI Auto Pilots
Is OBIO in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$31.2M
+1007.4% vs a year ago
Net income
−$57.0M
−182.5% margin
EPS (diluted)
−$0.75
Free cash flow
−$64.2M
−205.7% margin
Valuation
Market cap
$548.6M
78.7M shares
P/E
–
No P/E while losing money
Price to sales
17.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$27.8M
At Sep 30
Debt
$21.2M
At Sep 30
Shares outstanding
78.7M
At Nov 9
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $3.5M$3.5MFY2022FY2023: $2.8M$2.8MFY2023FY2024: $2.6M$2.6MFY2024FY2025: $33.5M$33.5MFY2025

From OBIO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on OBIO in the past 90 days
Average 12-month target
$11.67
▲ 67.4% upside

Based on 3 analysts who set a price target on OBIO in the past 90 days. The average target is $11.67, with a high of $12.00 and a low of $11.00, compared with the last close of $6.97.

Low $11.00Avg $11.67High $12.00
Blue marker: last close $6.97
Highest target$12.00
Average target$11.67
Lowest target$11.00
Latest rating changes
HC Wainwright & Co.Maintained
Nov 13Buy$12
BTIGTarget raised
Nov 13Buy$10 → $12
B. Riley SecuritiesMaintained
Sep 15Buy$11
BTIGUpgrade
Sep 10Buy$10
Piper SandlerReiterated
Aug 11Buy$10
DateFirmActionRatingPrice target
Nov 13HC Wainwright & Co.MaintainedBuy$12
Nov 13BTIGTarget raisedBuy$10 → $12
Sep 15B. Riley SecuritiesMaintainedBuy$11
Sep 10BTIGUpgradeBuy$10
Aug 11Piper SandlerReiteratedBuy$10
Loading…

Technical Analysis

OBIO · as of the Nov 17 close · updated after every close
Uptrend, nearing overbought

The stock is 14% above its 20 day and 15% above its 50 day average. It is 33% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 66), near overbought. The nearest support is the Pivot S1 at $6.82, and the nearest resistance the Pivot at $7.09.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityHigh, 6.7%/day
Key levels
$7.4552 week high+6.9%
$7.24Pivot R1+3.9%
$7.09Pivot+1.7%
$6.97Last close
$6.82Pivot S1−2.2%
$5.9820 day average−14.2%
$5.9450 day average−14.8%
$5.75Swing low (Sep 24)−17.5%
$5.17100 day average−25.8%
$4.66200 day average−33.1%
$3.4652 week low−50.4%
Indicators
RSI (14)65.88Strong, overbought above 70Neutral
MACD0.27Above its signal lineBullish
Stochastic86.6Near the top of its rangeOverbought
ADX (14)18.2No clear trend
Williams %R-20.8Oversold below −80, overbought above −20Neutral
CCI (20)215.4Oversold below −100, overbought above 100Overbought
Rate of change+25.4%Change over 10 sessionsBullish
ATR (14)$0.47Typical daily range, 6.7% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for OBIO

What happened before

See how OBIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow OBIO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How OBIO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in OBIO in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$144K
Largest print
$144K
Loading…

OBIO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲57 buying vs 29 selling
  • ▲Held by funds +4.5 pts
  • ▲Funds holding +16
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9377+20.8%
In funds' top 1010–
Held by funds39.7%35.2%+4.5 pts
New / increased26 / 3125 / 22+21.3%
Reduced / sold out19 / 1015 / 13+3.6%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See OBIO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OBIO is in one of them and how their past OBIO trades turned out.

OBIO in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered OBIO in an article yet. Here's the latest on the wider market.

About Orchestra BioMed Holdings

Orchestra BioMed is a biomedical company based in New Hope, Pennsylvania, that develops medical device therapies. Its main candidates are AVIM Therapy, a bioelectronic treatment for high blood pressure that can be added to cardiac pacemakers as a software update, and Virtue SAB, a drug and device balloon for treating narrowed arteries. The company works with large medical device makers, including Medtronic, to bring these technologies to patients. Both products are still in clinical study and have not yet been approved by regulators.

Headquarters
New Hope, PA